General
Preferred name
COPANLISIB
Synonyms
BAY 84-1236, BAY-80-6946, BAY 80-6946, Copanlisib hydrochloride ()
BAY 80-6946 dihydrochloride ()
Copanlisib dihydrochloride ()
BAY 80-6946 ()
BAY 80-6946 (dihydrochloride) ()
COPANLISIB HYDROCHLORIDE ()
Copanlisib (dihydrochloride) ()
BAY-80-6946 ()
BAY80-6946 ()
Copanlisib hydrochloride hydrate ()
BAY-80-6946 DIHYDROCHLORIDE ()
BAY-84-1236 ()
BAY 84-1236 ()
Aliqopa ()
P&D ID
PD012595
CAS
1032568-63-0
1402152-13-9
Tags
available
drug
Approved by
FDA
First approval
2017
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. (PKIDB)
DESCRIPTION Copanlisib hydrochloride is a potent inhibitor of Class I phosphoinositide 3-kinase which showed a therapeutic effect on non-Hodgkin lymphoma. It was approved to treat follicular lymphoma that has relapsed after treatment with at least two other anticancer therapies. (BOC Sciences Bioactive Compounds)
Cell lines
5
Organisms
0
Compound Sets
18
AdooQ Bioactive Compound Library
A11766
BOC Sciences Bioactive Compounds
copanlisib-hydrochloride-cas-1402152-13-9-item-7199
Cayman Chemical Bioactives
20354
ChEMBL Approved Drugs
CHEMBL3218576
CHEMBL3545068
ChEMBL Drugs
CHEMBL3218576
CHEMBL3545068
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DB12483
DrugBank Approved Drugs
DB12483
DrugCentral
5256
DrugCentral Approved Drugs
5256
EUbOPEN Chemogenomics Library
EUB0001179
MedChem Express Bioactive Compound Library
HY-15346
HY-15346A
NCATS Inxight Approved Drugs
WI6V529FZ9
NIH Approved Oncology Drugs
PKIDB
ReFrame library
TargetMol Bioactive Compound Library
T14998
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
480.22
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
2
cLogP
0.66
TPSA
139.79
Fraction CSP3
0.43
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
PIK3CA,PIK3CB,PIK3CD,PIK3CG
Pathway
PI3K/Akt/mTOR signaling
Apoptosis
PI3K/Akt/mTOR
Target
PI3K??
MTOR
PI3K¦Á
PI3K¦Â
PI3K¦Ã
PI3K¦Ä
PIK3CA, PIK3CB, PIK3CD, PIK3CG
PI3K
PIK3CA
PIK3CB
Indication
follicular lymphoma
MOA
PI3K inhibitor
Recommended Cell Concentration
100 nM
Source data